Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials.

Our findings suggest that there is no evidence of significant bias for PROs due to the absence of blinding in the context of PCa RCTs. Further analyses should be conducted in other cancer disease sites.